Effects of Remifentanil on Cardiac Function in Patients With Diastolic Dysfunction

• Status: Recruiting
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study ASA 1, 2 individuals with grade 1 or 2 diastolic dysfunction will be recruited to assess the effects of Remifentanil infusion on left ventricular function evaluated with transthoracic echocardiagraphy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yeditepe University
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• 60 years of age or older ASA 1, 2 adults with first or second degree diastolic dysfunction.

Exclusion Criteria:

• Atrial fibrillation, Atrioventricular block, tachyarrhythmia, bradyarrhythmia, Left ventricular ejection fraction lower than 50%, body mass index >30 kg/m2, Liver, kidney and lung disease.